Stockscreener 앱 받기
8.27
0.00%
0.00
시간 외 거래:
8.30
0.03
+0.36%
전일 마감가:
$8.27
열려 있는:
$8.27
하루 거래량:
3.09M
Relative Volume:
0.97
시가총액:
$1.74B
수익:
$557.51M
순이익/손실:
$-35.71M
주가수익비율:
-45.94
EPS:
-0.18
순현금흐름:
$15.50M
1주 성능:
-0.48%
1개월 성능:
-1.08%
6개월 성능:
+2.73%
1년 성능:
+1.72%
1일 변동 폭
$8.14
$8.355
1주일 범위
$8.02
$8.47
52주 변동 폭
$6.015
$11.31
바이오크리스트 Stock (BCRX) Company Profile
명칭
Biocryst Pharmaceuticals Inc
전화
919-859-1302
주소
4505 EMPEROR BOULEVARD, DURHAM, NC
BCRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
8.27 | 1.74B | 557.51M | -35.71M | 15.50M | -0.18 |
|
ZTS
Zoetis Inc
|
153.32 | 67.90B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.40 | 48.29B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.80 | 44.04B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.95 | 21.20B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
400.52 | 17.21B | 2.99B | 1.21B | 1.13B | 25.06 |
바이오크리스트 Stock (BCRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-02-25 | 개시 | Wedbush | Outperform |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-09-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-13 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-02-22 | 업그레이드 | Needham | Hold → Buy |
| 2022-11-02 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2022-08-05 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-08-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-04-18 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-04-11 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-12-10 | 개시 | Oppenheimer | Outperform |
| 2021-08-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-08-03 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-03-01 | 개시 | Cowen | Outperform |
| 2020-09-29 | 재개 | JP Morgan | Overweight |
| 2020-06-17 | 개시 | BTIG Research | Neutral |
| 2020-05-05 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-11-15 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | 재개 | Piper Jaffray | Overweight |
| 2018-08-08 | 재개 | JP Morgan | Overweight |
| 2018-07-17 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | 개시 | Seaport Global Securities | Neutral |
| 2018-01-02 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | 개시 | Barclays | Equal Weight |
| 2017-09-15 | 개시 | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2017-09-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2017-02-16 | 개시 | Ladenburg Thalmann | Buy |
| 2016-08-12 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | 재확인 | FBR Capital | Outperform |
| 2016-02-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2016-02-09 | 다운그레이드 | Needham | Buy → Hold |
모두보기
바이오크리스트 주식(BCRX)의 최신 뉴스
Forecasting BioCryst Pharmaceuticals Inc. price range with options dataJuly 2025 Closing Moves & High Return Stock Watch Alerts - Newser
Is a relief rally coming for BioCryst Pharmaceuticals Inc. holdersJuly 2025 Short Interest & Safe Capital Growth Trade Ideas - Newser
Will BioCryst Pharmaceuticals Inc. outperform its industry peersJuly 2025 Review & Low Risk Entry Point Tips - خودرو بانک
Understanding BioCryst Pharmaceuticals Inc.’s price movementProduct Launch & Advanced Technical Signal Analysis - Newser
BioCryst Pharmaceuticals, Inc. (BCRX) Q2 Revenue Soars 49%, Hits Record $163.4 Million on ORLADEYO Surge - MSN
Is BioCryst Pharmaceuticals Inc. forming bullish engulfing patternsJuly 2025 Market Mood & Growth Focused Entry Point Reports - خودرو بانک
Does BioCryst Pharmaceuticals Inc. stock reflect fundamentalsJuly 2025 Levels & Precise Swing Trade Alerts - خودرو بانک
Can technical indicators confirm BioCryst Pharmaceuticals Inc.’s reversalJuly 2025 Breakouts & High Yield Equity Trading Tips - Newser
Is BioCryst Pharmaceuticals Inc. affected by consumer sentiment2025 Support & Resistance & Free Weekly Watchlist of Top Performers - خودرو بانک
BioCryst Pharmaceuticals Stock (BCRX) Opinions on Q2 Revenue Surge and Conference Insights - Quiver Quantitative
BioCryst at Cantor Global Healthcare Conference: Strategic Growth and Opportunities - Investing.com Canada
BioCryst Pharmaceuticals: A High-Growth Biotech Play with a Strong Pipeline and Strategic Financial Moves - AInvest
Transcript : BioCryst Pharmaceuticals, Inc. Presents at Cantor Global Healthcare Conference 2025, Sep-04-2025 09 - MarketScreener
Order flow analysis tools used on BioCryst Pharmaceuticals Inc.2025 Year in Review & Verified Stock Trade Ideas - Newser
Can BioCryst Pharmaceuticals Inc. stock double in the next yearProfit Target & Smart Investment Allocation Insights - خودرو بانک
Is BioCryst Pharmaceuticals Inc. forming a breakout pattern2025 Trading Volume Trends & Consistent Profit Focused Trading Strategies - خودرو بانک
Will BioCryst Pharmaceuticals Inc. see short term momentum2025 Geopolitical Influence & Free Real-Time Volume Trigger Notifications - Newser
What are BioCryst Pharmaceuticals Inc.’s earnings expectationsJuly 2025 Momentum & Fast Entry Momentum Trade Alerts - خودرو بانک
Can you recover from losses in BioCryst Pharmaceuticals Inc.Chart Signals & Smart Money Movement Tracker - Newser
Published on: 2025-09-04 04:25:22 - Newser
Is BioCryst Pharmaceuticals Inc. still worth holding after the dipGold Moves & Detailed Earnings Play Alerts - Newser
Best data tools to analyze BioCryst Pharmaceuticals Inc. stockWeekly Volume Report & Weekly High Conviction Ideas - Newser
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
71,400 RSUs and 36,700 Stock Options: BioCryst's Latest Employee Compensation Package Details - Stock Titan
Applying Elliott Wave Theory to BioCryst Pharmaceuticals Inc.Gap Up & Daily Profit Maximizing Trade Tips - Newser
What to do if you’re stuck in BioCryst Pharmaceuticals Inc.Earnings Risk Report & Expert Approved Trade Ideas - Newser
BioCryst Pharmaceuticals Inc. stock prediction for this weekEarnings Growth Summary & AI Driven Stock Movement Reports - Newser
How to read the order book for BioCryst Pharmaceuticals Inc.Trade Analysis Report & Daily Growth Stock Investment Tips - Newser
Is BioCryst Pharmaceuticals Inc. a defensive stockJuly 2025 Analyst Calls & Stock Portfolio Risk Management - خودرو بانک
Fibrodysplasia Ossificans Market to Experience Notable Growth in Forecast Span by 2032, DelveInsight Predicts | Ipsen, Regeneron Pharma, Biocryst - Barchart.com
Will BioCryst Pharmaceuticals Inc. benefit from rising consumer demandMarket Performance Report & Risk Controlled Stock Pick Alerts - خودرو بانک
How to build a custom watchlist for BioCryst Pharmaceuticals Inc.July 2025 Decliners & Expert Verified Stock Movement Alerts - Newser
Custom watchlist performance reports with BioCryst Pharmaceuticals Inc.2025 Support & Resistance & Daily Risk Controlled Trade Plans - Newser
Is BioCryst Pharmaceuticals Inc. backed by strong institutional buyingOptions Play & Daily Stock Momentum Reports - خودرو بانک
Is BioCryst Pharmaceuticals Inc.’s growth already priced in2025 Market Sentiment & Stock Market Timing Techniques - خودرو بانک
BioCryst Pharmaceuticals Inc. Inches Above Key Support — Safe to Hold getLinesFromResByArray error: size == 0 - 강소기업뉴스
What is BioCryst Pharmaceuticals Inc.’s TAM (Total Addressable Market)Quarterly Market Summary & AI Driven Price Predictions - خودرو بانک
Published on: 2025-09-01 00:02:12 - Newser
What to do if you’re stuck in BioCryst Pharmaceuticals IncTrade Risk Summary & Long-Term Capital Growth Ideas - Newser
How to track smart money flows in BioCryst Pharmaceuticals Inc.2025 Market Outlook & Reliable Breakout Forecasts - Newser
Leading vs lagging indicators on BioCryst Pharmaceuticals Inc. performanceEarnings Recap Report & Daily Profit Focused Screening - Newser
Will BioCryst Pharmaceuticals Inc. stock benefit from AI tech trendsGDP Growth & Weekly Chart Analysis and Guides - Newser
Published on: 2025-08-31 13:57:41 - Newser
Chart based exit strategy for BioCryst Pharmaceuticals Inc.Market Risk Summary & Technical Confirmation Alerts - Newser
Published on: 2025-08-31 12:26:45 - Newser
바이오크리스트 (BCRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
바이오크리스트 주식 (BCRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| HEGGIE THERESA | Director |
Aug 13 '25 |
Sale |
8.51 |
70,000 |
595,868 |
65,352 |
3.53%
자본화:
|
볼륨(24시간):